Neumora Therapeutics CEO Henry Gosebruch announced that the company’s experimental major depression treatment failed its first Phase 3 clinical trial. The results marked a setback for the neuroscience drug developer, which had high hopes for its therapy. This is not the first time Neumora has faced challenges in its pipeline; previous trials have also shown mixed results. Despite this, the company remains committed to advancing its research and will continue with the remaining two Phase 3 trials.
Source: https://endpts.com/neumoras-major-depression-drug-flunks-first-of-three-phase-3-trials